Indonesia Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Indonesia Diabetes Drugs Market Report is Segmented by Drug Class (Oral Anti-Diabetics, Insulins, Combination Drugs and Non-Insulin Injectable Drugs), Diabetes Type (Type-1 Diabetes and Type-2 Diabetes), and Distribution Channel (Hospital Pharmacies, Retail Chain Pharmacies and Online Pharmacies). The Market Forecasts are Provided in Terms of Value (USD).

Indonesia Diabetes Drugs Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

Compare market size and growth of Indonesia Diabetes Drugs Market with other markets in Healthcare Industry

Indonesia Diabetes Drugs Market Analysis by Mordor Intelligence

The Indonesia diabetes drugs market stood at USD 387.13 million in 2025 and is forecast to reach USD 527.51 million by 2030, advancing at a 6.34% CAGR. The steady climb is underpinned by the country’s status as the world’s fifth-largest diabetes population, universal insurance coverage through BPJS Kesehatan, and expanding local manufacturing capacity. Prescription volumes keep rising as older adults account for most new diagnoses, while novel GLP-1 and SGLT-2 agents win clinical acceptance in urban hospitals. Greater domestic production of active pharmaceutical ingredients (APIs), a push toward halal-certified drugs, and aggressive digital-health roll-outs add further momentum to the Indonesia diabetes drugs market.[1]Indonesia.go.id, “Cegah Dini Ancaman Diabetes,” Indonesia.go.id

Key Report Takeaways

  • By drug class, oral anti-diabetic medicines led with a 42.36% revenue share in 2024; non-insulin injectables are poised to expand at an 8.67% CAGR through 2030. 
  • By diabetes type, Type 2 cases captured 93.47% of the Indonesia diabetes drugs market share in 2024, while the same segment is projected to grow at a 7.32% CAGR up to 2030. 
  • By distribution channel, hospital pharmacies held 49.88% of 2024 revenue; online pharmacies are set to post a 10.05% CAGR over the forecast window.

Segment Analysis

By Drug Class: Oral Medications Drive Volume While Injectables Capture Value

The Indonesia diabetes drugs market size for oral therapies reached USD 164 million in 2024, equal to a 42.36% revenue slice. Metformin (33.85% prescription rate) and glimepiride dominate first-line choices, aided by inclusion on the national e-Fornas list.[3]e-Fornas Kemkes, “Daftar Obat Nasional,” e-fornas.kemkes.go.id Uptake of fixed-dose combinations is rising as physicians seek one-pill dosing to reinforce adherence among multi-morbidity seniors. In parallel, non-insulin injectables book the fastest trajectory, with an 8.67% CAGR linked to GLP-1 and dual-agonist trial activity. LeaderMed and Combiphar’s Phase 3 study of LM-008—from September 2024—underscores local appetite for next-generation injectables. Premium analogue insulin retains a narrow but lucrative share because 35% of users prefer premixed pens for convenience.

Intensified competition around value-added injectables changes hospital formularies, especially in Jakarta and Bandung, where specialist panels now weigh cardiovascular-outcome data more heavily. Pharmaceutical groups answer with patient-assistance schemes and bundled glucometer packages, tactics that deepen loyalty but squeeze margins. Local API plants could improve gross margins for oral tablets; however, complex peptides for injectables still depend on imported intermediates, limiting immediate price relief.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Diabetes Type: Type 2 Dominance Reflects Epidemiological Reality

Type 2 diabetes generated 93.47% of 2024 prescriptions, making it the unquestioned anchor segment for the Indonesia diabetes drugs market. Its projected 7.32% CAGR to 2030 outpaces population growth due to earlier onset in urban millennials and longer life expectancy among seniors. Government plans for free early-detection check-ups starting 2025 will swell the diagnosed base, ensuring steady demand in primary care. The Indonesia diabetes drugs market size for Type 2 therapies consequently heads for USD 490 million by 2030, lifting overall revenues. Conversely, Type 1 accounts for fewer than 42,000 recorded patients yet commands higher per-capita spending because of lifelong insulin dependence. Gestational diabetes, currently 2.6% of cases, gains policy attention as maternal-health programs integrate mandatory glucose screening. These patient-subgroup trends shape formulation pipelines: low-GI nutraceuticals appear alongside premix insulins for pregnant women, while pediatric pen devices improve usability for young Type 1 patients.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Distribution Channel: Digital Transformation Reshapes Access Patterns

Hospital outlets processed 49.88% of diabetes prescriptions in 2024, reflecting Indonesia’s physician-centric care model. Large urban hospitals hold formularies that extend beyond JKN-mandated minimums, offering GLP-1 and combination injectables. Yet online channels are now the fastest mover, expanding at a 10.05% CAGR as Halodoc and K24klik push click-to-doorstep delivery. Integration with BPJS e-scripts eliminates cash flow choke-points and surfaces adherence reminders, advantages especially valuable to rural patients. Retail chains such as Apotek K-24 capture mid-tier consumers seeking after-hours service, and plan 1,000 outlets by 2026 to cement geographic reach. Within three years, omnichannel models that blend teleconsults, e-payments, and same-day delivery should account for a meaningful slice of the Indonesia diabetes drugs market size, particularly for refill medications where convenience trumps in-person counseling.

Market Segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Geography Analysis

Java remains the epicenter of both disease burden and commercial activity, housing the bulk of specialist centers and nearly all API plants. Jakarta clinics lead in prescribing analogue insulin and GLP-1 agents, a shift driven by higher disposable incomes and greater cardiology liaison services. Java-based PT Kimia Farma Sungwoon Pharmacopia’s API output reduces logistic hurdles for downstream manufacturers, allowing quicker cycle times for metformin and glimepiride tablet runs. Sumatra and Kalimantan markets trail but show above-average growth as mining-boom towns raise household incomes and private insurance uptake. Telehealth penetration accelerates in Sulawesi and Maluku, regions where ferry linkages lengthen physical delivery timelines yet mobile-network coverage is robust.

The Ministry of Health’s plan for nationwide free medical screening pools funding to reach remote islands. Mobile clinics equipped with HbA1c testing devices will likely boost early diagnoses in Papua, nudging consumption of low-cost generics first, then stepping up into combination therapies as disease progresses. On the supply side, distribution chains diversify via cold-chain refurbishments at secondary ports, reducing spoilage for insulin shipments. As geographic disparities narrow, the Indonesia diabetes drugs market benefits from a broader, more stable base of treated patients.

Competitive Landscape

Domestic enterprises together held large share of 2024 sales, underlining a moderate-concentration pattern. PT Kalbe Farma leverages its salesforce scale to embed Diabetasol across retail and hospital accounts, while state-owned Bio Farma enjoys preferential access to public tenders. PT Kimia Farma’s API venture enhances vertical integration, though profitability headwinds prompted factory rationalizations in 2024. For multinationals, localization is no longer optional; Novo Nordisk’s insulin-packaging line inside Bio Farma’s Bandung site highlights how foreign innovators adapt to 70% local-content mandates. Pfizer and MSD explore similar technology-transfer models, with the latter already finalizing a pneumococcal-vaccine accord that may extend to diabetes therapies. 

Digital engagement is a rising competitive lever. Halodoc forms alliances with chain pharmacies to guarantee 24-hour delivery, while start-ups in Yogyakarta test AI-based adherence apps for metformin regimens. Halal certification represents a looming hurdle: brands that complete audits early gain retail advantages among Muslim consumers. Lastly, branded-generic promotion battles escalate at primary-care clinics, where detailing budgets tilt toward patient-education events rather than physician lunches, reflecting stricter compliance norms.

Indonesia Diabetes Drugs Industry Leaders

  1. Eli Lilly

  2. Sanofi

  3. Novo Nordisk

  4. PT Kalbe Farma Tbk

  5. Merck & Co.

  6. *Disclaimer: Major Players sorted in no particular order
Indonesia Diabetes Care Drugs Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • January 2025: The Ministry of Industry outlined a roadmap and tax-incentive package to shrink API imports to below 70% within two years, earmarking grants for R&D pilot plants.
  • September 2024: LeaderMed and Combiphar formed a joint venture to run Indonesian Phase 3 trials of LM-008, a dual GLP-1 agonist, aiming at first-in-class approval by 2027.
  • July 2024: Novo Nordisk partnered with Bio Farma to commence local insulin packaging for distribution to nearly 1 million patients over 10 years.

Table of Contents for Indonesia Diabetes Drugs Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Diabetes Prevalence & Aging Population
    • 4.2.2 Government Initiatives and Insurance Programs
    • 4.2.3 Uptake of Novel GLP-1 & SGLT-2 Therapies
    • 4.2.4 Growing Penetration of Branded-Generics
    • 4.2.5 Improved Medical Education and Clinical Guidelines
    • 4.2.6 Local Manufacturing Partnerships and Local “fill-and-finish” Insulin Partnerships
  • 4.3 Market Restraints
    • 4.3.1 90 % API Import Dependence Inflates COGS
    • 4.3.2 High Out-of-pocket Cost for Analogue Insulin
    • 4.3.3 Physician CME Gap Slows Adoption of New Drugs
    • 4.3.4 Patent-cliff Uncertainty Deters Local Investors
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Drug Class
    • 5.1.1 Oral Anti-Diabetic Drugs
    • 5.1.2 Insulins
    • 5.1.3 Combination Drugs
    • 5.1.4 Non-Insulin Injectables
  • 5.2 By Diabetes Type
    • 5.2.1 Type 1 Diabetes
    • 5.2.2 Type 2 Diabetes
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Chain Pharmacies
    • 5.3.3 Online Pharmacies

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 Novo Nordisk A/S
    • 6.3.2 PT Kalbe Farma Tbk
    • 6.3.3 Sanofi
    • 6.3.4 Eli Lilly and Company
    • 6.3.5 Merck & Co.
    • 6.3.6 AstraZeneca
    • 6.3.7 Boehringer Ingelheim
    • 6.3.8 Takeda
    • 6.3.9 Pfizer
    • 6.3.10 Janssen Pharmaceuticals
    • 6.3.11 Lupin
    • 6.3.12 Novartis
    • 6.3.13 Glenmark
    • 6.3.14 PT Dexa Medica
    • 6.3.15 PT Kimia Farma Tbk
    • 6.3.16 PT Phapros Tbk
    • 6.3.17 Astellas

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Indonesia Diabetes Drugs Market Report Scope

Diabetes Drugs are used to manage diabetes mellitus by lowering the glucose level in the blood. The Indonesia Diabetes Care Drugs Market is segmented into drugs (Insulin, Oral anti-diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs). The report offers the value (USD) and volume (Units) for the above segments.

By Drug Class Oral Anti-Diabetic Drugs
Insulins
Combination Drugs
Non-Insulin Injectables
By Diabetes Type Type 1 Diabetes
Type 2 Diabetes
By Distribution Channel Hospital Pharmacies
Retail Chain Pharmacies
Online Pharmacies
By Drug Class
Oral Anti-Diabetic Drugs
Insulins
Combination Drugs
Non-Insulin Injectables
By Diabetes Type
Type 1 Diabetes
Type 2 Diabetes
By Distribution Channel
Hospital Pharmacies
Retail Chain Pharmacies
Online Pharmacies
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current value of the Indonesia diabetes drugs market?

The market was valued at USD 387.13 million in 2025 and is projected to climb to USD 527.51 million by 2030.

2. Which therapeutic class dominates prescriptions in Indonesia?

Oral anti-diabetic medicines lead with a 42.36% share, largely driven by metformin and sulfonylureas.

3. How fast are online pharmacies growing in diabetes drug distribution?

Online channels are advancing at a 10.05% CAGR, the quickest among all distribution segments.

4. What share do domestic manufacturers hold?

Indonesian firms collectively capture 75% of national diabetes-drug revenue, buoyed by branded-generic strategies.

5. Why are GLP-1 and SGLT-2 therapies gaining ground?

Strong cardio-renal outcome data, CME campaigns, and widening formulary inclusion fuel their adoption in major urban hospitals.

6. How does government policy support diabetes care expansion?

Universal insurance via BPJS Kesehatan, mandatory early screening, and local-content rules for pharmaceuticals collectively widen patient access while promoting domestic production.

Indonesia Diabetes Drugs Market Report Snapshots